EGFR and non-small cell lung carcinoma: The combination of bevacizumab and erlotinib demonstrated superior PFS in patients with EGFR mutation-positive stage IIIB/IV non-squamous cell carcinoma NSCLC, when compared with erlotinib monotherapy (16.0 months vs. 9.7 months).